Erlotinib Hydrochloride Patent Expiration
Erlotinib Hydrochloride is used for treating locally advanced unresectable or metastatic pancreatic cancer, metastatic non-small cell lung cancer with specific mutations, and maintenance treatment in lung cancer patients who have not progressed on platinum-based chemotherapy. It was first introduced by Osi Pharmaceuticals Llc
Erlotinib Hydrochloride Patents
Given below is the list of patents protecting Erlotinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tarceva |
US6900221 (Pediatric) | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
May 09, 2021
(Expired) | Osi Pharms |
| Tarceva |
US7087613 (Pediatric) | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
May 09, 2021
(Expired) | Osi Pharms |
| Tarceva | US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
Nov 09, 2020
(Expired) | Osi Pharms |
| Tarceva | US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
Nov 09, 2020
(Expired) | Osi Pharms |
| Tarceva |
US5747498 (Pediatric) | Alkynyl and azido-substituted 4-anilinoquinazolines |
May 08, 2019
(Expired) | Osi Pharms |
| Tarceva |
USRE41065 (Pediatric) | Alkynl and azido-substituted 4-anilinoquinazolines |
May 08, 2019
(Expired) | Osi Pharms |
| Tarceva | US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines |
Nov 08, 2018
(Expired) | Osi Pharms |
| Tarceva | USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines |
Nov 08, 2018
(Expired) | Osi Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Erlotinib Hydrochloride's patents.
Latest Legal Activities on Erlotinib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Erlotinib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2018 | US7087613 |
| Patent Issue Date Used in PTA Calculation Critical
| 08 Aug, 2006 | US7087613 |
| Recordation of Patent Grant Mailed Critical
| 08 Aug, 2006 | US7087613 |
| Issue Notification Mailed Critical
| 19 Jul, 2006 | US7087613 |
| Application Is Considered Ready for Issue Critical
| 05 Jul, 2006 | US7087613 |
| Dispatch to FDC | 05 Jul, 2006 | US7087613 |
| Issue Fee Payment Received Critical
| 07 Jun, 2006 | US7087613 |
| Issue Fee Payment Verified Critical
| 07 Jun, 2006 | US7087613 |
| Correction - Drawing NOT Required | 09 Mar, 2006 | US7087613 |
| Mail Formal Drawings Required | 09 Mar, 2006 | US7087613 |
Erlotinib Hydrochloride's Family Patents
